Huntington's Disease Therapeutics

Published by	Global Industry Analysts, Inc.
Published	April, 2010	Product code	121147
Content info	Pages: 311
Price	US $ 3950 PDF by E-mail (Single user license) US $ 11850 PDF By E-mail (Global License to Company and its Fully-owned Subsidiaries)

Introduction
Related Reports

Huntington's Disease Therapeutics published by Global Industry Analysts, Inc. in April, 2010. This report consists of Pages: 311 and the price starts from US $ 3950.

Introduction

Abstract

This report analyzes the Global market forHuntington' s Disease Therapeutics in US$ Million. Annual estimates and forecasts are provided for the period 2009 through 2015. The report profiles 37 companies including Alnylam Pharmaceuticals, Inc., Amarin Corporation, Plc, Avicena Group, Inc., Biovail Corporation, Ceregene, Inc., Cortex Pharmaceuticals, Inc., H. Lundbeck A/S, Intellect Neurosciences Incorporation, Medivation, Inc., NeuroSearch A/S, Prana Biotechnology Limited, Raptor Pharmaceuticals Corp., Targeted Genetics Corporation, Trophos SA, and Vertex Pharmaceuticals Incorporated. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

A Prelude
Market Opportunity
Unmet Clinical Needs to Foster R&D Engine
Support Organizations Play An Instrumental Role
Improved Diagnostics Boosts HD Management
Competition in the Global HD Market is Nonexistent
Reimbursement Issues for HD
Effectiveness of Current HD Management Strategies
Affordability of Xenazine Will Be Key for Sustained Uptake
Off-Label Prescriptions
Select Off-Label Drugs Prescribed for Huntington' s Disease
Rising Interest in HD Drugs Development
Drug Development Pipeline Reveals A Promising Picture
Public-Private Partnerships: A Shot in the Arm
Dimebon™ Candidacy As a Potent HD Drug Appear Doubtful
Drugs in Pipeline
HD-02
Huntexil™ (Pridopidine or ACR16)
OXIGON™
AMR101 (Miraxion™)
DR Cysteamine
PBT2
Select Pipeline Drugs for Treatment of Huntington' s Disease As of 2009
Promising Research Breakthroughs
Lundbeck Announces Successful Open-Label Results for Xenazine
UCLA Scientists Identify Molecular Switch to Check Huntington' s Disease in Mice
Molecular Switch Capable of Blocking Huntington' s Disease Identified
Novel Drug Targets Recognized for Huntington' s Disease
First Transgenic Monkey Model of Huntington' s Disease Developed
Other Novel Approaches for HD Treatment
CERE-120
Cellular Delivery of Neurotropic Agents
Cogane
COPREXA
Histone Deacetylases (HDAC)
Melatonin, Coenzyme Q-Free Radical Scavengers
Minocycline - Caspase Inhibition
RNAi - RNA Interference
Small Molecule Inhibitor of Polyglutamine Interaction
TELOMICS™

2. AN OVERVIEW OF HUNTINGTON' S DISEASE

Introduction
Historical Background
Prognosis
Stages of HD
Symptoms and Signs
Physical Symptoms
Emotional Symptoms
Mental Symptoms
Genetics of Huntington' s Disease
Inheritance
Mechanism
Functions of HTT
Effects of mHTT on Cells
Macroscopic Effects of mHTT
Diagnosis of HD
Clinical Diagnosis
Embryonic Diagnosis
Differential Diagnosis
Diagnostic Tests for Huntington' s Disease
Confirmatory Diagnostic Test
Pre-symptomatic Diagnostic Test
Prenatal Diagnostic Test
Treatment Options
Nutrition and Eating
Social Activity
Speech Therapy
Physical Therapy
Occupational Therapy
Medication

3. PRODUCT INTRODUCTIONS/CLINICAL TRIALS

Suven Life Sciences Secures Two Patents in the US
Medivation and Pfizer Begin Phase III Trial of Dimebon
Alnylam and Medtronic Present New Preclinical Data on ALN-HTT
NeuroSearch Presents ACR16 as Novel Huntington' s Disease Therapy
Raptor Pharmaceuticals Receives FDA Orphan Drug Designation for Cysteamine
NeuroSearch Receives Approval from EMEA for Huntexil™as New Brand Name for Pridopidine
KeyNeurotek Pharmaceuticals Elucidates on Molecular Pathomechanism of Huntingtin' s Mutation
NeuroSearch Begins Critical Phase III Program with ACR16
Avicena Proceeds to NIH Sponsored Phase III Trial for HD-02
EnVivo Pharmaceuticals Progresses on Major HDACi Program
NeuroSearch Files CTA in Europe to Begin Clinical Phase III Program with ACR16

4. RECENT INDUSTRY ACTIVITY

Alliance Pharma to Acquire Cambridge Laboratories
Alliance Pharma Concludes Distribution Deal With Biovail
Lundbeck Acquires LifeHealth
Lundbeck Acquires Ovation
Biovail Purchases Global Rights for Tetrabenazine from Cambridge
Raptor Pharmaceuticals, TorreyPines Concluded Merger
Cambridge Laboratories Enters into New Agreements for Marketing Xenazine® in North America
CHDI Foundation Inks Agreement with AMRI for Drug Discovery
Phytopharm Inks Agreement with CHDI Foundation to Evaluate Cogane
NeuroSearch Repurchases Global Rights to ACR16
Raptor Pharmaceuticals Enters into Collaboration with Centre Hospitalier Universitaire d' Angers for Phase II Clinical Trial
Targeted Genetics Acquires Full Rights from Sirna Therapeutics to siRNA Development Program
Cambridge Laboratories Receives Marketing Approval for Tetrabenazine from Agencia Espanola de Medicamentos y Productos Sanitarios
Cambridge Laboratories Inks and Renews Agreements with Taiwan, New Zealand, Finland and Australia
CHDI Inked Collaboration Agreements with Galapagos
Biovail Acquires Prestwick Pharmaceuticals
Ovation Pharmaceuticals Acquires License to Commercialize Xenazine® in the US
Aegera Therapeutics Inks License Agreement with Neurologix
Intellect Neurosciences Inks Agreement with CHDI Foundation to Evaluate Potential of OXIGON™
Pipex Pharmaceuticals Entered into CRADA with Veterans Affairs Medical Center for Evaluation of COPREXA

5. FOCUS ON SELECT PLAYERS

Alnylam Pharmaceuticals, Inc. (USA)
Amarin Corporation, Plc (Ireland)
Avicena Group, Inc. (USA)
Biovail Corporation (Canada)
Ceregene, Inc. (USA)
Cortex Pharmaceuticals, Inc. (USA)
H. Lundbeck A/S (Denmark)
- Intellect Neurosciences Incorporation (USA)
- Medivation, Inc (USA)
- NeuroSearch A/S (Denmark)
- Prana Biotechnology Limited (Australia)
- Raptor Pharmaceuticals Corp. (USA)
- Targeted Genetics Corporation (USA)
- Trophos SA (France)
- Vertex Pharmaceuticals Incorporated (USA)

6. GLOBAL MARKET PERSPECTIVE

Table 1: Global Current and Future Analysis for Huntington' s Disease Therapeutics with Annual Revenue Figures in US$ Million for Years 2009 through 2015 (includes corresponding Graph/Chart)